advertisement
AIM: To determine the prevalence of ocular neovascularization following CRAO. BACKGROUND: Debate exists in the literature of the prevalence and aetiology of neovascularisation following central retinal artery occlusion (CRAO). The reported prevalence varies from 2.5% to 31.6%. We conducted a retrospective study to determine the prevalence of ocular neovascularization following acute CRAO in our institution. METHODS: A retrospective audit of consecutive patients with non-arteritic/thromboembolic CRAO presenting between 1997 and 2009 in a single tertiary teaching hospital. RESULTS: Thirty-three patients were identified as having non-arteritic CRAO, and of this cohort 6 patients (18.2%) developed ocular neovascularisation. Neovascular glaucoma was present in 5 cases (15.2%); two of these presented through an emergency department with painful eyes, both at 16 weeks post CRAO. The other cases of neovascularization were detected on scheduled follow-ups. Mean time from retinal occlusive event to observed neovascularization was 8.5 weeks (range 2-16 weeks). One case of neovascularisation was associated with haemodynamically significant ipsilateral carotid stenosis; no patients had proliferative diabetic retinopathy or other causes of NV demonstrated. CONCLUSION: The prevalence of NV following acute CRAO in our population was 18.2% at an average of 8.5 weeks post CRAO. There was a temporal relationship between the two events and no other causes of NV demonstrable in our cohort of patients. There is no consensus on the follow up regime post CRAO to detect the ocular NV complications. Our study suggests that NV can occur early and regular follow-up especially in the first 4 months are important post CRAO.
C.S. Chen. Department of Stroke Neurology, NHandMRC Centre of Clinical Eye Research, Flinders University, Flinders Drive, Bedford ParkAustralia.
9.4.5.1 Neovascular glaucoma (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous)